Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
Barrail-Tran A, Goldwirt L, Gelé T, Laforest C, Lavenu A, Danjou H, Radenne S, Leroy V, Houssel-Debry P, Duvoux C, Kamar N, De Ledinghen V, Canva V, Conti F, Durand F, D'Alteroche L, Botta-Fridlund D, Moreno C, Cagnot C, Samuel D, Fougerou-Leurent C, Pageaux GP, Duclos-Vallée JC, Taburet AM, Coilly A. Barrail-Tran A, et al. Eur J Clin Pharmacol. 2019 Nov;75(11):1555-1563. doi: 10.1007/s00228-019-02725-x. Epub 2019 Aug 5. Eur J Clin Pharmacol. 2019. PMID: 31384986
Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial.
Atwine D, Baudin E, Gelé T, Muyindike W, Mworozi K, Kyohairwe R, Kananura K, Orikiriza P, Nyehangane D, K T Nanjebe D, Furlan V, Verstuyft C, Barrail-Tran A, Taburet AM, Bonnet M; ANRS 12292 Rifavirenz study group. Atwine D, et al. J Antimicrob Chemother. 2020 May 1;75(5):1250-1258. doi: 10.1093/jac/dkz557. J Antimicrob Chemother. 2020. PMID: 31999314 Clinical Trial.
Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records.
Bertrand J, Barrail-Tran A, Fayette L, Savic R, Goujard C, Teicher E, Barau C, Pruvost A, Taburet AM, Mentré F, Verstuyft C. Bertrand J, et al. Among authors: barrail tran a. Antimicrob Agents Chemother. 2023 May 17;67(5):e0233918. doi: 10.1128/aac.02339-18. Epub 2023 Apr 26. Antimicrob Agents Chemother. 2023. PMID: 37098914 Free PMC article.
Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
Savic RM, Barrail-Tran A, Duval X, Nembot G, Panhard X, Descamps D, Verstuyft C, Vrijens B, Taburet AM, Goujard C, Mentré F; ANRS 134–COPHAR 3 Study Group. Savic RM, et al. Clin Pharmacol Ther. 2012 Nov;92(5):575-83. doi: 10.1038/clpt.2012.137. Epub 2012 Oct 3. Clin Pharmacol Ther. 2012. PMID: 23033116 Free PMC article. Clinical Trial.
[Evidence-based therapeutic drug monitoring for indinavir].
Barrail-Tran A, Taburet AM, Poirier JM; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique. Barrail-Tran A, et al. Therapie. 2011 May-Jun;66(3):239-46. doi: 10.2515/therapie/2011035. Epub 2011 Aug 9. Therapie. 2011. PMID: 21819808 Review. French.
Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.
Goldwirt L, Braun J, de Castro N, Charreau I, Barrail-Tran A, Delaugerre C, Raffi F, Lascoux-Combe C, Aboulker JP, Taburet AM, Molina JM. Goldwirt L, et al. Antimicrob Agents Chemother. 2011 Jul;55(7):3613-5. doi: 10.1128/AAC.01827-10. Epub 2011 May 16. Antimicrob Agents Chemother. 2011. PMID: 21576452 Free PMC article.
54 results